Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02140515 |
Recruitment Status : Unknown
Verified August 2012 by Royan Institute.
Recruitment status was: Recruiting
First Posted : May 16, 2014
Last Update Posted : May 6, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infertility | Drug: Lutropin alfa Drug: Follitropin alfa and Lutropin alfa | Phase 4 |
In this single blind randomized clinical trial, 90 women with a clinical history of hypogonadotrophic hypogonadism who stopped any treatment with gonadotrophins >1 month before study, with a negative progesterone challenge test, low serum gonadotrophins (Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) less than 5.0 IU/l) and oestradiol (less than 100 pg/ml) and normal serum concentrations of thyroid stimulating hormone (TSH), testosterone and prolactin within 6 months before the start of treatment are studied in the Royan Institute. Other causes of infertility are excluded from the study. All patients receive treatment with recombinant follicle stimulating hormone (Gonal-F) and recombinant luteinizing hormone (Luveris). When at least one follicle reaches 14 mm in diameter, 4mg/day oestradiol is administered and patients are randomly divided into two groups: Luveris alone (intervention group) and continued treatment with both drugs Gonal-F and Luveris (control group). When at least one follicle detects a mean diameter of ≥18 mm and serum estradiol level reaches 500-2000 pg/ml, ovarian stimulation is stopped and injection of 10000 IU Human Chorionic Gonadotrophin (hCG) is administrated.
At the end, the number and size of ovarian follicles, endometrial thickness on the day of injection of Human Chorionic Gonadotrophin (hCG), the number of oocytes retrieved, the number of good quality embryos, chemical and clinical pregnancy rate, fertilization rate and implantation rate will be compared between the two groups.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism |
Study Start Date : | November 2012 |
Estimated Primary Completion Date : | December 2015 |
Estimated Study Completion Date : | November 2016 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Luveris
Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
|
Drug: Lutropin alfa
Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
Other Name: Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH) |
Active Comparator: Gonal-F& Luveris
Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
|
Drug: Follitropin alfa and Lutropin alfa
Administration of (rFSH) and (rLH)
Other Names:
|
- number of follicles [ Time Frame: baseline ]Evaluation thre number follicles before injection of Human Chorionic Gonadotrophin (hCG)
- Size of follicle [ Time Frame: baseline ]Evaluation the size of follicle before injection of Human Chorionic Gonadotrophin (hCG)
- Endometrial thickness [ Time Frame: 1day ]Evaluation the endometrial thickness at the day of injection of Human Chorionic Gonadotrophin (hCG)
- number of oocytes retrieved [ Time Frame: 3 days ]Evaluation the number of oocytes retrieved 34-36 hours after Human Chorionic Gonadotrophin (hCG) injection
- Fertilization rate [ Time Frame: 2 days ]Evaluation the fertilization rate 2-3 days before the embryo transfer
- Biochemical pregnancy rate [ Time Frame: 2 weeks ]Evaluation the biochemical pregnancy rate 2 weeks after embryo transfer
- Clinical pregnancy rate [ Time Frame: 4 weeks ]Evaluation the clinical pregnancy rate 4-6 weeks after embryo transfer
- Implantation rate [ Time Frame: 4 weeks ]Evaluation the implantation rate 4-6 weeks after embryo transfer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result comply with diagnosis of hypogonadotropic hypogonadism
- Have discontinued gonadotropins or gonadotropin releasing hormone or estrogen-progesterone replacement therapy at least one month before the study
- Have primary or secondary amenorrhea
- Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) <5.0 IU/l and oestradiol <100 pg/ml before initiation of treatment
- Have a negative progesterone challenge test
- Normal serum concentrations of thyroid stimulating hormone (TSH), prolactin and testosterone within 6 months before the start of study
- Be willing and able to comply with the protocol for the duration of the study
- Have given written informed consent prior to any study related procedure
Exclusion Criteria:
- The other causes of infertility.
- History of ovarian hyper stimulation syndrome
- Abnormal gynecological bleeding of undetermined origin
- Previous or current hormone dependent tumor
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02140515
Contact: Nasser Aghdami, MD,PhD | (+98)2123562000 ext 516 | nasser.aghdami@royaninstitute.org | |
Contact: Leila Arab, MD | (+98)2123562000 ext 414 | Leara91@gmail.com |
Iran, Islamic Republic of | |
Royan Institute | Recruiting |
Tehran, Iran, Islamic Republic of | |
Contact: Nasser Aghdami, MD,PhD (+98)2123562000 ext 516 nasser.aghdami@royaninstitute.org | |
Contact: Leila Arab, m (+98)23562000 ext 414 Leara91@gmail.com | |
Sub-Investigator: Reza Khalili, PhD | |
Sub-Investigator: Jhaleh Etminan, Bsc | |
Sub-Investigator: sdamaneh Jalali, BSc |
Study Chair: | Hamid Gourabi, PhD | Head of Royan Institute | |
Study Director: | Tahereh Madani, MD | Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. | |
Principal Investigator: | Seyedeh Masoumeh Moosavi Sadat, MSc | Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran |
Responsible Party: | Royan Institute |
ClinicalTrials.gov Identifier: | NCT02140515 |
Other Study ID Numbers: |
royan-Emb-018 |
First Posted: | May 16, 2014 Key Record Dates |
Last Update Posted: | May 6, 2015 |
Last Verified: | August 2012 |
Gonal-F Luveris Assisted Reproductive Technology Hypogonadotropic Hypogonadism |
Infertility Hypogonadism Genital Diseases Urogenital Diseases Gonadal Disorders |
Endocrine System Diseases Hormones Follicle Stimulating Hormone Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |